Free tool
FAERS Monitor: Veozah
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216578 or its brand name (Veozah, Fezolinetant). Reports on generic versions are filed under their own applications.
Reports
2,301
Serious
466
20% of reports
Hospitalization
88
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective281
- hepatic enzyme increased217
- alanine aminotransferase increased200
- aspartate aminotransferase increased153
- headache130
- off label use124
- nausea110
- hot flush107
- liver function test increased98
- insomnia94
- diarrhoea86
- fatigue84
- abdominal pain72
- dizziness67
- back pain56
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 186 |
| 2024 | 736 |
| 2025 | 800 |
| 2026 | 576 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,858 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| liver function test increasedSignal | 98 | 41.9 | 34.5 | 3,859 |
| alanine aminotransferase increasedSignal | 200 | 29.9 | 26.2 | 5,550 |
| hepatic enzyme increasedSignal | 217 | 29.2 | 25.7 | 5,879 |
| aspartate aminotransferase increasedSignal | 153 | 26.4 | 22.7 | 3,713 |
| hot flushSignal | 107 | 13.0 | 10.8 | 1,175 |
| insomniaSignal | 94 | 3.2 | 2.6 | 144 |
| abdominal painSignal | 72 | 2.8 | 2.3 | 84 |
| back painSignal | 56 | 2.2 | 1.7 | 36 |
| drug ineffective | 281 | 1.9 | 1.7 | 138 |
| headache | 130 | 1.9 | 1.6 | 56 |
| off label use | 124 | 1.3 | 1.1 | 8 |
| nausea | 110 | 1.3 | 1.1 | 6 |
| dizziness | 67 | 1.2 | 1.0 | 3 |
| diarrhoea | 86 | 1.2 | 1.0 | 3 |
| fatigue | 84 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.